Your browser is no longer supported. Please, upgrade your browser.
Settings
EDIT Editas Medicine, Inc. daily Stock Chart
EDIT [NASD]
Editas Medicine, Inc.
Index- P/E- EPS (ttm)-3.09 Insider Own0.30% Shs Outstand43.24M Perf Week-12.79%
Market Cap754.54M Forward P/E- EPS next Y-2.65 Insider Trans-79.52% Shs Float35.69M Perf Month-8.11%
Income-110.50M PEG- EPS next Q-0.62 Inst Own81.30% Short Float14.55% Perf Quarter-36.01%
Sales5.90M P/S127.89 EPS this Y-47.00% Inst Trans20.29% Short Ratio5.61 Perf Half Y11.43%
Book/sh5.66 P/B3.08 EPS next Y3.30% ROA-39.60% Target Price41.00 Perf Year-47.52%
Cash/sh8.13 P/C2.15 EPS next 5Y- ROE-63.30% 52W Range12.43 - 38.25 Perf YTD7.52%
Dividend- P/FCF28.69 EPS past 5Y- ROI-54.10% 52W High-54.38% Beta-
Dividend %- Quick Ratio7.00 Sales past 5Y- Gross Margin- 52W Low40.39% ATR1.06
Employees89 Current Ratio7.00 Sales Q/Q-12.50% Oper. Margin- RSI (14)41.63 Volatility6.50% 5.38%
OptionableYes Debt/Eq0.24 EPS Q/Q-6.70% Profit Margin- Rel Volume1.20 Prev Close17.91
ShortableYes LT Debt/Eq0.16 EarningsMay 15 AMC Payout- Avg Volume926.50K Price17.45
Recom2.40 SMA20-8.48% SMA50-15.05% SMA200-3.82% Volume1,108,540 Change-2.57%
Mar-28-17Initiated Chardan Capital Markets Buy $65
Aug-10-16Upgrade Jefferies Hold → Buy
Jun-02-16Initiated Jefferies Hold
Feb-29-16Initiated Morgan Stanley Equal-Weight $28
Feb-29-16Initiated JP Morgan Neutral
Feb-29-16Initiated JMP Securities Mkt Outperform
May-16-17 01:40PM  Is Editas Facing a New Reality in CRISPR Land? 24/7 Wall St. -8.55%
09:34AM  Biotech Movers: Akebia, Editas, Novavax TheStreet.com
May-15-17 07:05PM  Edited Transcript of EDIT earnings conference call or presentation 15-May-17 9:00pm GMT Thomson Reuters StreetEvents
06:32PM  Editas reports 1Q loss Associated Press
04:01PM  Editas Medicine Announces First Quarter 2017 Results and Update GlobeNewswire
03:30PM  Investor Network: Editas Medicine, Inc. to Host Earnings Call Accesswire
May-13-17 11:05AM  Editas Medicine Demonstrates First Achievement of In Vivo Editing in Non-human Primate Retinas GlobeNewswire
May-12-17 08:45AM  Why Editas Medicine (EDIT) Might Surprise This Earnings Season Zacks
May-11-17 09:15AM  Editas Medicine Announces Pre-Clinical Data for Program to Treat Sickle Cell Disease and Beta-Thalassemia GlobeNewswire
May-09-17 05:42PM  Allergan Says It Continues to Look at Stepping-Stone Deals TheStreet.com
09:48AM  Perrigo Company (PRGO) Q1 Earnings: Disappointment in Store? Zacks
May-08-17 04:01PM  Editas Medicine to Present at Investor Conferences in May GlobeNewswire
04:01PM  Editas Medicine to Host Conference Call Discussing First Quarter 2017 Corporate Update and Results GlobeNewswire
02:45PM  Cambridge gene editing firm CRISPR to use delivery tech honed at MIT American City Business Journals
Apr-27-17 11:35AM  CEOs of top gene-editing firms got huge compensation hikes last year American City Business Journals
Apr-25-17 09:29AM  Opening Bell, April 25, 2017 CNBC Videos
09:15AM  Today's Bell Ringer, April 25, 2017 CNBC Videos
Apr-24-17 02:18PM  Editas Medicine to Present New Data Demonstrating Advancements for Translating CRISPR Technologies into Medicines at the American Society of Gene & Cell Therapy Annual Meeting GlobeNewswire
10:00AM  Editas Medicine, Inc. (Nasdaq: EDIT) to Ring The Nasdaq Stock Market Opening Bell GlobeNewswire
Apr-13-17 02:05PM  Editas foes add legal firepower as gene-editing case goes to appeal American City Business Journals
Mar-31-17 04:09PM  EDITAS MEDICINE, INC. Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under an Off-Bal
Mar-30-17 07:20AM  New Cambridge biotech Tango aims to make cancer its own worst enemy at bizjournals.com
07:20AM  New Cambridge biotech Tango aims to make cancer its own worst enemy American City Business Journals
Mar-29-17 08:11AM  Editas Medicine, Inc. breached its 50 day moving average in a Bullish Manner : EDIT-US : March 29, 2017 Capital Cube
08:11AM  Editas Medicine, Inc. breached its 50 day moving average in a Bullish Manner : EDIT-US : March 29, 2017
Mar-28-17 06:04AM  Coverage initiated on Editas Medicine by Chardan Capital Markets +5.75%
Mar-22-17 10:30AM  Latest Editas research pact could be worth up to $1 billion at bizjournals.com
10:30AM  Latest Editas research pact could be worth up to $1 billion American City Business Journals
Mar-20-17 04:51PM  Editas Get A Vetr Upgrade To Strong Buy Benzinga
Mar-17-17 04:50PM  EDITAS MEDICINE, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial Stateme -10.48%
Mar-16-17 09:05PM  Editas Medicine, Inc. Announces Pricing of $90 Million Offering of Common Stock GlobeNewswire
02:12PM  [$$] EGenesis Raises $38 Million Series A, Targets Organ Shortage The Wall Street Journal
02:12PM  [$$] EGenesis Raises $38 Million Series A, Targets Organ Shortage at The Wall Street Journal
12:50AM  Pig organs in humans? George Church-founded biotech banks $38M to try at bizjournals.com
12:50AM  Pig organs in humans? George Church-founded biotech banks $38M to try American City Business Journals
Mar-15-17 05:46PM  Allergan (AGN) and Editas Tie Up to Treat Eye Diseases Zacks -5.38%
04:14PM  Editas Medicine, Inc., Announces Proposed Offering of Common Stock GlobeNewswire
08:46AM  EDITAS MEDICINE, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement
Mar-14-17 05:24PM  Here's Why Editas Medicine Gained as Much as 17.2% Today at Motley Fool
04:30PM  Allergan plc and Editas Medicine Inc Enter into Strategic R&D Alliance to Discover and Develop CRISPR Genome Editing Medicines for Eye Diseases Call scheduled for 4:30 pm ET today
11:25AM  CRISPR Could Change The World, But Right Now $90 Million Is Enough at Forbes
11:15AM  Allergan, Editas In Gene-Editing Eye Disease Pact at Investopedia
09:59AM  Allergan, Editas Sign Gene-Editing Pact for Rare Eye Diseases
09:26AM  Biotech Premarket Movers: Editas, Amphastar, Aratana, Pacira
09:00AM  Editas bags $90M in gene editing R&D pact with Allergan at bizjournals.com
08:35AM  Editas Medicine surges 8% on $90 million Allergan research and development deal at MarketWatch
08:22AM  Allergan signs deal with Editas for gene-editing-based eye treatments
08:00AM  Allergan and Editas Medicine Enter into Strategic R&D Alliance to Discover and Develop CRISPR Genome Editing Medicines for Eye Diseases PR Newswire
Mar-09-17 01:04PM  EDITAS MEDICINE, INC. Financials +8.02%
10:41AM  Editas Medicine, Inc. :EDIT-US: Earnings Analysis: Q4, 2016 By the Numbers : March 9, 2017
Mar-08-17 02:50PM  Intellia R&D head says new gene-editing data shows path to human trials at bizjournals.com
12:53AM  Edited Transcript of EDIT earnings conference call or presentation 7-Mar-17 10:00pm GMT
Mar-07-17 07:46PM  Editas reports 4Q loss
05:00PM  Editas Medicine Inc Earnings Call scheduled for 5:00 pm ET today
04:10PM  EDITAS MEDICINE, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibi
04:01PM  Editas Medicine Announces Fourth Quarter and Full Year 2016 Results and Update GlobeNewswire
07:07AM  Q4 2016 Editas Medicine Inc Earnings Release - After Market Close
Mar-06-17 01:00PM  New Cambridge-based, Third Rock-backed biotech revealed in federal filing at bizjournals.com
12:31PM  3 Stocks I'd Never Touch at Motley Fool
Mar-03-17 09:10AM  Editas Medicine COO to Leave Company -6.81%
09:07AM  EDITAS MEDICINE, INC. Files SEC form 8-K, Change in Directors or Principal Officers
09:00AM  Editas Medicine Announces Departure of Chief Operating Officer GlobeNewswire
Feb-28-17 04:01PM  Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2016 Corporate Update and Results GlobeNewswire +8.39%
08:00AM  Editas Medicine Joins Global Movement to Raise Awareness on Rare Disease Day 2017 GlobeNewswire
Feb-27-17 04:01PM  Editas Medicine to Present at Investor Conferences in March GlobeNewswire
Feb-21-17 05:00AM  How Much Is a CRISPR Patent License Worth? at Forbes
Feb-17-17 02:36PM  Court Rules Against Berkeley In CRISPR Patent Case at Investopedia +5.13%
Feb-16-17 05:45PM  Here's Why Editas Medicine Jumped 32.6% Higher Today at Motley Fool
01:34PM  Both sides claim victory angling for millions in potential royalties and licenses in gene-editing patent dispute at bizjournals.com
Feb-15-17 05:29PM  Gene editing patent ruling sways fortune of biotech hopefuls +28.84%
04:33PM  Why Fortress Investment Group, Editas Medicine, and Hertz Global Holdings Jumped Today at Motley Fool
03:52PM  Stop Freaking Out About CRISPR! (Except For One Thing) at Forbes
03:19PM  Editas Medicine's stock soars after favorable ruling in CRISPR patent dispute at MarketWatch
02:37PM  Broad Institute wins case over gene-editing patents, boosting Editas shares at bizjournals.com
01:58PM  Editas Medicine Announces U.S. Patent and Trademark Office Decision Favorable to Broad Institute in CRISPR Interference GlobeNewswire
Feb-14-17 11:00AM  Use Gene Tools for Disease, Not Designer Babies, Panel Says at Bloomberg
Feb-10-17 04:01PM  Editas Medicine to Present at Upcoming February Investor Conferences GlobeNewswire
Feb-07-17 06:21PM  Why Crisper Therapeutics Tumbled 12.4% in January at Motley Fool
Feb-01-17 05:00AM  How A 2015 Trial Sheds Light On The CRISPR Patent Case at Forbes
Jan-23-17 04:07PM  EDITAS MEDICINE, INC. Files SEC form 8-K, Financial Statements and Exhibits
Jan-13-17 12:46PM  10 Most Interesting Companies In The World at Insider Monkey
Jan-10-17 03:33PM  Editas CEO: Our goal is to repair broken genes at the lev...
Jan-09-17 08:00AM  Editas Medicine Reports on Recent Progress and 2017 Goals at J.P. Morgan Healthcare Conference GlobeNewswire +5.03%
Jan-05-17 02:40PM  Here's what to expect from Mass. biotechs at this weekend's J.P. Morgan conference at bizjournals.com -5.24%
08:18AM  Editas Medicine (EDIT) Shares March Higher, Can It Continue?
Jan-04-17 08:01AM  Editas Medicine to Present at the 35th Annual J.P. Morgan Healthcare Conference GlobeNewswire +8.57%
Dec-21-16 08:01AM  EDITAS MEDICINE, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial
Dec-19-16 02:35PM  A better approach to gene editing? Editas snags new exclusive license from Broad at bizjournals.com
07:00AM  Editas Medicine Extends CRISPR Genome Editing Leadership Through Licensing of New CRISPR Technologies GlobeNewswire
Dec-16-16 12:00PM  Gene-editing firms form patent alliance against Editas, Broad at bizjournals.com
Dec-15-16 12:20AM  A new name and new fund will ensure Cambridge's Flagship 'feels like a startup' at bizjournals.com
12:01AM  Flagship Ventures Evolves Name To Flagship Pioneering PR Newswire
Dec-09-16 06:36AM  Here is What Hedge Funds Think About Editas Medicine Inc (EDIT) at Insider Monkey
Dec-06-16 03:19PM  Is This Why CRISPR Therapeutics Stock Rallied 21.6% in November? at Motley Fool
Dec-01-16 10:59AM  ETFs with exposure to Editas Medicine, Inc. : December 1, 2016
Nov-30-16 07:34AM  Editas Medicine, Inc. breached its 50 day moving average in a Bearish Manner : EDIT-US : November 30, 2016
Nov-23-16 01:10PM  Shares of Seattle, Waltham biotech Juno crash after patient deaths at bizjournals.com
11:00AM  Is Editas Medicine (EDIT) Stock a Solid Choice Right Now?
Nov-15-16 04:11PM  Chinese Pioneer First Human Gene Edit, Triggering Biotech Space Race (CRSP, EDIT) at Investopedia
Nov-14-16 05:41PM  [$$] Partners Innovation Fund Raises $39M at The Wall Street Journal
Developing gene editing therapies based on CRISPR/Cas9 technology.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Glucksmann AlexandraChief Operating OfficerMar 15Option Exercise0.651,000650118,788Mar 17 11:53 AM
Glucksmann AlexandraChief Operating OfficerMar 15Sale26.411,00026,410117,788Mar 17 11:53 AM
Glucksmann AlexandraChief Operating OfficerFeb 15Option Exercise0.656,0003,900123,788Feb 16 06:39 PM
Hack Andrew A. F.Chief Financial OfficerFeb 15Option Exercise3.233,0009,6903,000Feb 16 06:41 PM
Hack Andrew A. F.Chief Financial OfficerFeb 15Sale19.203,00057,6000Feb 16 06:41 PM
Glucksmann AlexandraChief Operating OfficerFeb 15Sale20.586,000123,484117,788Feb 16 06:39 PM
Hack Andrew A. F.Chief Financial OfficerJan 11Option Exercise3.2315,00048,45015,000Jan 13 04:41 PM
Hack Andrew A. F.Chief Financial OfficerJan 11Sale19.2015,000288,0000Jan 13 04:41 PM
Polaris Venture Management Co.10% OwnerDec 07Sale15.8275,0001,186,5003,797,144Dec 08 05:07 PM
Bitterman KevinDirectorDec 07Sale15.8275,0001,186,5003,797,144Dec 08 05:07 PM
Polaris Venture Management Co.10% OwnerDec 06Sale15.8750,000793,5003,872,144Dec 07 04:44 PM
Bitterman KevinDirectorDec 06Sale15.8750,000793,5003,872,144Dec 07 04:43 PM
Polaris Venture Management Co.10% OwnerDec 05Sale15.7480,0001,259,2003,922,144Dec 07 04:44 PM
Bitterman KevinDirectorDec 05Sale15.7480,0001,259,2003,922,144Dec 07 04:43 PM
Polaris Venture Management Co.10% OwnerNov 23Sale15.7121,480337,4514,002,144Nov 28 04:37 PM
Bitterman KevinDirectorNov 23Sale15.7121,480337,4514,002,144Nov 28 04:35 PM
Polaris Venture Management Co.10% OwnerNov 22Sale15.7712,819202,1564,023,624Nov 23 04:38 PM
Bitterman KevinDirectorNov 22Sale15.7712,819202,1564,023,624Nov 23 04:36 PM
Polaris Venture Management Co.10% OwnerNov 16Sale16.3030,830502,5294,036,443Nov 18 05:46 PM
Bitterman KevinDirectorNov 16Sale16.3030,830502,5294,036,443Nov 18 05:44 PM
Bitterman KevinDirectorNov 15Sale16.5730,865511,4284,067,273Nov 16 04:47 PM
Polaris Venture Management Co.10% OwnerNov 15Sale16.5730,865511,4284,067,273Nov 16 04:47 PM
Bitterman KevinDirectorNov 14Sale17.1658,035995,8814,098,138Nov 16 04:47 PM
Polaris Venture Management Co.10% OwnerNov 14Sale17.1658,035995,8814,098,138Nov 16 04:47 PM